Kvols Larry K
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33615, USA.
J Nucl Med. 2005 Jan;46 Suppl 1:187S-90S.
The ideal radiation sensitizer would reach the tumor in adequate concentrations and act selectively in the tumor compared with normal tissue. It would have predictable pharmacokinetics for timing with radiation treatment and could be administered with every radiation treatment. The ideal radiation sensitizer would have minimal toxicity itself and minimal or manageable enhancement of radiation toxicity. The ideal radiation sensitizer does not exist today. This review outlines the concept of combining 2 modalities of cancer treatment, radiation and drug therapy, to provide enhanced tumor cell kill in the treatment of human malignancies and discusses molecules that target DNA and non-DNA targets. Combining drugs that have unique mechanisms of action and absence of overlapping toxicities with systemically administered radiotherapy should be exploited in future clinical trials. This is an exciting time in clinical oncology research, because we have a plethora of new molecules to evaluate.
理想的放射增敏剂应能以足够的浓度到达肿瘤部位,并与正常组织相比在肿瘤中具有选择性作用。它应具有可预测的药代动力学,以便与放射治疗同步,并且每次放射治疗时都能给药。理想的放射增敏剂自身毒性应最小,对放射毒性的增强作用应最小或易于控制。目前尚不存在理想的放射增敏剂。本综述概述了将放射治疗和药物治疗这两种癌症治疗方式相结合的概念,以在人类恶性肿瘤治疗中增强肿瘤细胞杀伤,并讨论了靶向DNA和非DNA靶点的分子。在未来的临床试验中,应利用具有独特作用机制且无重叠毒性的药物与全身放射治疗相结合。这是临床肿瘤学研究中令人兴奋的时期,因为我们有大量新分子有待评估。